Infant Bacterial Therapeutics AB(SE:IBT.B)
kr 69.40-1.60 (-2.25%)
SE:IBT.B
Infant Bacterial Therapeutics AB financials statements
kr 69.40
At close:-1.60 (-2.25%)
Want to see SE:IBT.B full AI Analyst Report?
Infant Bacterial Therapeutics AB (IBT.B) Ratios
0 Followers
Infant Bacterial Therapeutics AB Ratios
SE:IBT.B's free cash flow for Q2 2026 was kr-23.19M. For the 2026 fiscal year, SE:IBT.B's free cash flow was increased by kr0.00 and operating cash flow was kr-23.19M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.72 | 3.33 | 7.40 | 18.93 | 30.03 |
| Quick Ratio | 2.72 | 3.33 | 7.40 | 18.93 | 30.03 |
| Cash Ratio | 2.55 | 3.22 | 7.13 | 18.75 | 29.25 |
| Solvency Ratio | -1.14 | 0.12 | 0.25 | -3.61 | -3.34 |
| Operating Cash Flow Ratio | -1.28 | -1.63 | -2.19 | -4.79 | -4.21 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | kr 97.19M | kr 161.31M | kr 295.38M | kr 321.12M | kr 383.87M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.54 | 1.41 | 1.15 | 1.05 | 1.03 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -219.60 | -105.96 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -224.60 | -107.94 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.03 | 0.04 |
| Net Debt to EBITDA | 2.11 | 1.63 | -28.49 | 5.22 | 8.84 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| EBIT Margin | 0.00% | -3422625.00% | -159828.57% | -545425.00% | 0.00% |
| EBITDA Margin | 0.00% | -3422625.00% | 14998.70% | -536183.33% | 0.00% |
| Operating Profit Margin | 0.00% | -3497550.00% | -174827.27% | -548400.00% | 0.00% |
| Pretax Profit Margin | 0.00% | -3422625.00% | -159828.57% | -545425.00% | 0.00% |
| Net Profit Margin | 0.00% | -3422625.00% | -159828.57% | -545425.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -3422625.00% | -159828.57% | -545425.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 105.19% | 97.86% | 91.42% | 99.46% | 100.93% |
| Return on Assets (ROA) | -40.29% | -57.15% | -35.03% | -18.72% | -11.01% |
| Return on Equity (ROE) | -61.87% | -80.41% | -40.33% | -19.73% | -11.38% |
| Return on Capital Employed (ROCE) | -58.82% | -82.17% | -44.11% | -19.84% | -11.28% |
| Return on Invested Capital (ROIC) | -58.82% | -82.17% | -44.11% | -19.84% | -11.28% |
| Return on Tangible Assets | -42.40% | -59.35% | -36.02% | -19.30% | -11.33% |
| Earnings Yield | -9.58% | -18.96% | -11.06% | -11.66% | -6.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 434897.50 | 31930.39 | 54080.83 | 0.00 |
| Days of Sales Outstanding | 0.00 | 434897.50 | 31930.39 | 54080.83 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 434897.50 | 31930.39 | 54080.83 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -5.37 | -8.40 | -8.19 | -7.64 | -4.95 |
| Free Cash Flow Per Share | -5.37 | -8.40 | -8.19 | -7.64 | -4.95 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | -28283.25 | -1314.53 | -7149.58 | 0.00 |
| Free Cash Flow Yield | -10.63% | -15.67% | -9.10% | -15.28% | -7.42% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -10.43 | -5.28 | -9.04 | -8.58 | -16.67 |
| Price-to-Sales (P/S) Ratio | 0.00 | 180517.03 | 14452.15 | 46775.77 | 0.00 |
| Price-to-Book (P/B) Ratio | 6.46 | 4.24 | 3.65 | 1.69 | 1.90 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.40 | -6.38 | -10.99 | -6.54 | -13.48 |
| Price-to-Operating Cash Flow Ratio | -9.40 | -6.38 | -10.99 | -6.54 | -13.48 |
| Price-to-Earnings Growth (PEG) Ratio | 0.20 | -2.50 | -0.13 | -0.19 | 0.44 |
| Enterprise Value Multiple | -7.87 | -3.64 | 67.86 | -3.50 | -8.30 |
| Enterprise Value | 536.30M | 498.68M | 783.75M | 225.47M | 363.16M |
| EV to EBITDA | -7.87 | -3.64 | 67.86 | -3.50 | -8.30 |
| EV to Sales | 0.00 | 124670.03 | 10178.59 | 18789.10 | 0.00 |
| EV to Free Cash Flow | -7.41 | -4.41 | -7.74 | -2.63 | -6.53 |
| EV to Operating Cash Flow | -7.41 | -4.41 | -7.74 | -2.63 | -6.53 |
| Tangible Book Value Per Share | 7.22 | 11.98 | 23.89 | 28.61 | 34.20 |
| Shareholders’ Equity Per Share | 7.82 | 12.64 | 24.68 | 29.55 | 35.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Net Income Per Share | -4.84 | -10.16 | -9.95 | -5.83 | -4.01 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.94 | 1.00 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 30151.50 | 1573.81 | 5485.00 | 0.00 |
| SG&A to Revenue | 0.00 | 4824.00 | 175.47 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.11 | 0.78 | 0.82 | 1.30 | 1.25 |
Currency in SEK

